Pernix Therapeutics Holdings (PTX) Posts Q2 GAAP Loss of 16c/Share

Pernix Therapeutics Holdings (NASDAQ: PTX) reported Q2 EPS of ($0.16), $0.11 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $17.4 million versus the consensus estimate of $26.2 million.

For earnings history and earnings-related data on Pernix Therapeutics Holdings (PTX) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• RBC cuts Northrop Grumman rating on slower growth, cautious defense outlook
• Reaction roundup: Experts, analysts weigh in on September jobs report